ProCE Banner Series

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

Join us for this live CME/CPE/CE/ABIM MOC and ABPath–certified workshop series reviewing the best practices and latest advances in the management of lung or thyroid cancers with NTRK or RET gene fusions. Register today!

  ACPE
  | AMA
  | ANCC
Who Should Attend

This program is intended for medical oncologists, pathologists, endocrinologists, surgeons, interventional radiologists, nurses, pharmacists, and other healthcare professionals who care for patients with lung or thyroid cancer.

All Events

Past Events

January

25

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

4:00 PM - 6:00 PM Central Time (CT)

In-person

Private Event -- Texas Oncology - Dallas

January

26

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

12:30 PM - 2:00 PM Central Time (CT)

In-person

Private Event -- Adventist HealthCare Shady Grove Medical Center

February

08

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

11:30 AM - 12:30 PM Central Time (CT)

In-person

Private Event -- Ascension Providence Cancer Center

February

14

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

11:30 AM - 12:30 PM Central Time (CT)

In-person

Private Event -- Wise Health System

February

16

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

11:30 AM - 12:30 PM Central Time (CT)

Virtual

March

02

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy (PRIVATE)

4:00 PM - 5:00 PM Pacific Time (PT)

In-person

Private Event, San Mateo, California

March

07

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy (PRIVATE)

4:30 PM - 5:30 PM Mountain Time (MT)

In-person

Private Event, Rio Rancho, New Mexico

March

09

2023

Genomic Alterations in Lung and Thyroid Cancer: Guidance on Molecular Testing for Precision Therapy

11:30 AM - 12:30 PM Eastern Time (ET)

In-personVirtual

Private Event, Baltimore, Maryland

Topics

Welcome, Introduction, Polling Questions

Overview and Rationale for Testing for NTRK Gene Fusions

  • TRK biology and oncogenesis/NTRK fusion frequency and diagnosis across histologies
  • Clinical data and current indications for TRK inhibitors
  • Future directions

Overview and Rationale for Testing RET Gene Fusions

  • RET alterations and oncogenesis/RET fusion frequency and diagnosis across histologies
  • Clinical data and current indications for RET inhibitors
  • Future directions

Evidence Based Testing Strategies to Detect Appropriate Fusions and Mutations

  • Methods of detection of NTRK and RET fusions

Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and planning individualized treatment for patient with lung or thyroid cancers.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order appropriate assays or molecular tests to detect oncogenic gene fusions in patients with NSCLC and thyroid cancer
  • Appraise emerging clinical data supporting the use of TRK inhibition in NTRK fusion–positive NSCLC and thyroid cancer and RET inhibition in RET-altered lung and thyroid cancer
  • Formulate strategies for integrating TRK and RET inhibitors into the management of eligible patients with NSCLC and thyroid cancer, based on expert recommendations and oncogenic gene fusion status
  • Develop treatment strategies for patients with cancer who develop acquired resistance to first-generation TRK and RET inhibitor therapy
  • Manage treatment-related symptoms associated with the treatment of RET altered or NTRK fusion–positive cancer
  • Refer eligible patients with NTRK fusion–positive and RET-altered NSCLC and thyroid cancer for ongoing clinical trials

Accreditation

 

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-214-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC

In partnership with American Society for Clinical Pathology

Supported by educational grants from Bayer HealthCare Pharmaceuticals Inc.
Blueprint Medicines
Genentech, a member of the Roche Group
Lilly

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191